Aarti Industries Ltd reported a consolidated net profit of ₹1.06 billion for Q2 FY2026, with revenue from operations reaching ₹21 billion. The performance reflects early signs of margin recovery and stable demand across specialty chemicals and pharma segments, despite global headwinds.
Aarti Industries Ltd, a leading player in India’s specialty chemicals and pharmaceuticals space, posted its Q2 FY2026 results with revenue from operations at ₹21 billion and net profit of ₹1.06 billion. The company’s performance signals a gradual recovery in margins and demand stabilization across key verticals.
The quarter saw operating expenses decline by 6.96% QoQ, helping offset pressure from global inventory corrections and pricing volatility. Aarti’s pharma division continued to show resilience, while the specialty chemicals segment benefited from improved utilization and export traction.
Management remains focused on capacity expansion, long-term contracts, and cost optimization, with expectations of stronger performance in H2 FY2026. The company is also investing in green chemistry and sustainability-linked innovations to align with global ESG mandates.
Major Takeaways:
-
Revenue from Operations: ₹21 billion
-
Net Profit: ₹1.06 billion
-
Expense Trends: Operating costs down 6.96% QoQ
-
Segment Performance: Pharma stable; specialty chemicals recovering
-
Strategic Focus: Capacity expansion, ESG innovation, cost control
-
Outlook: Positive on margin recovery and export demand
Aarti Industries’ Q2 results reflect disciplined execution and strategic positioning in a volatile global environment.
Sources: LiveMint, Moneycontrol, Aarti Investor Relations